Captor Therapeutics Spolka Akcyjna (WSE:CTX)

WSE:CTX Income Statement

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	4.66	15.83	13.2	9.16	3.99
Revenue Growth (YoY)	-70.55%	19.88%	44.15%	129.75%	-
Cost of Revenue	1.45	5.23	6.3	2.09	0.74
Gross Profit	3.22	10.6	6.9	7.07	3.25
Selling, General & Admin	11.14	11.46	16.14	24.07	30.68
Research & Development	45.29	43.9	70.89	44.16	23.12
Other Operating Expenses	-9.57	-5.79	-7.11	-22.79	-17.71
Operating Expenses	46.85	49.56	79.92	45.44	36.09
Operating Income	-43.63	-38.97	-73.02	-38.36	-32.84
Interest Expense	-0.28	-0.39	-0.27	-0.32	-0.4
Interest & Investment Income	1.82	1.04	3.08	3.13	-
Currency Exchange Gain (Loss)	0.03	-0.07	-0.27	-0.08	-0.06
Other Non Operating Income (Expenses)	-0.01	-0.05	-0.05	-0.26	-0.41
EBT Excluding Unusual Items	-42.07	-38.43	-70.53	-35.89	-33.7
Gain (Loss) on Sale of Assets	0.07	-	-	-	-
Asset Writedown	-	-	-	-	1.13
Pretax Income	-42	-38.43	-70.53	-35.89	-32.57
Income Tax Expense	-	-	0.06	-	-
Net Income	-42	-38.43	-70.58	-35.89	-32.57
Net Income to Common	-42	-38.43	-70.58	-35.89	-32.57
Shares Outstanding (Basic)	6	5	5	4	4
Shares Outstanding (Diluted)	6	5	5	4	4
Shares Change (YoY)	18.42%	0.30%	11.46%	0.97%	14.99%
EPS (Basic)	-7.61	-8.25	-15.19	-8.61	-7.89
EPS (Diluted)	-7.61	-8.25	-15.19	-8.61	-7.89
Free Cash Flow	-37.53	-32.3	-55.21	-23.84	-33.59
Free Cash Flow Per Share	-6.80	-6.93	-11.88	-5.72	-8.14
Gross Margin	68.99%	66.95%	52.28%	77.21%	81.41%
Operating Margin	-936.33%	-246.24%	-553.11%	-418.91%	-823.88%
Profit Margin	-901.22%	-242.82%	-534.69%	-391.94%	-817.16%
Free Cash Flow Margin	-805.36%	-204.12%	-418.22%	-260.32%	-842.60%
EBITDA	-39.27	-33.91	-67.58	-31.27	-25.49
EBITDA Margin	-	-214.27%	-	-	-
D&A For EBITDA	4.37	5.06	5.44	7.09	7.36
EBIT	-43.63	-38.97	-73.02	-38.36	-32.84
EBIT Margin	-	-246.24%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.